Former Chemical Week colleague Rick Mullin, now a senior editor with Chemical and Engineering News, just wrote a nice piece profiling three individuals who are helping to bring drug manufacturing into the 21st century, by taking a more "operations" and "results" oriented approach.
They are: William Deese, President of Merck's manufacturing division, Novartis' Mark Fishman, President of Novartis' NIBR and Pfizer's Robin Spencer, who is bringing high throughput screening to more of the company's R&D efforts.
To read this update, click here.
-AMS
Latest from Home
Latest from Home